|
マルヤマ タクミ
Maruyama Takumi
丸山 拓実 所属 その他 その他 職種 薬剤師 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19. |
| 掲載誌名 | 正式名：Transplant immunology 略 称：Transpl Immunol ISSNコード：18785492/09663274 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 77,pp.101777 |
| 著者・共著者 | ARIMURA Ken, TAGAYA Etsuko, KIKUCHI Ken, MITSUDA Toshihiro, EBIHARA Fumiya, MARUYAMA Takumi, HAMADA Yukihiro, UNAGAMI Kohei, KANAZAWA Taichi, SEKIGUCHI Haruki, SHIMAMOTO Ken, ISHIDA Hideki, EGAWA Hiroto, TANAKA Junji, KAWANA Masatoshi |
| 発行年月 | 2023/04 |
| 概要 | INTRODUCTION:Transplant recipients (TRs) are at high risk for severe coronavirus disease 2019 (COVID-19). Neutralizing monoclonal antibodies (mAbs) are used for treating mild-to-moderate COVID-19. However, reports comparing the efficacy of COVID-19 treatment without/with mAbs in TRs are limited. We assessed the efficacy of casirivimab/imdevimab against mild-to-moderate COVID-19 in TRs.METHODS:Forty-one patients were retrospectively evaluated. The duration until defervescence, oxygen (O2) requirement ≥5 L, and neutralizing antibody levels were compared in TRs with COVID-19 without/with casirivimab/imdevimab.RESULTS:Casirivimab/imdevimab was correlated with shorter duration until defervescence and non-requirement of O2 ≥ 5 L in TRs with COVID-19 [mean: without/with: 6 vs. 2; P = 0.0002, hazard ratio (HR) = 0.3333, 95% confidence interval (CI) = 0.1763-0.6301; 15 vs. 8; P < 0.0001, HR = 0.5333, 95% CI = 0.2878-0.9883; P = 0.0377, HR = 0.1502, 95% CI = 0.02511-0.8980]. Casirivimab/imdevimab was associated with early defervescence after adjusting for sex and age (P = 0.013, HR = 0.412, 95% CI = 0.205-0.826). The antibody levels between patients without/with casirivimab/imdevimab on the day of hospitalization were not significantly different (P = 0.1055), including 13 TRs with vaccination. Antibody levels were higher in patients with casirivimab/imdevimab at 3-5 days after hospitalization than in those without, at 7-9 days after hospitalization (P < 0.0001, mean, without/with: 414.9/40000 AU/mL).CONCLUSION:Casirivimab/imdevimab was effective and increased the neutralizing antibody in TRs with mild-to-moderate COVID-19, it may contribute toward preventing the progression. |
| DOI | 10.1016/j.trim.2022.101777 |
| PMID | 36584927 |